• A must-attend, advanced-level, 2-day "immersion" training program specifically designed for executives from pharmaceutical, biotech or laboratory companies involved in lung cancer and/or head & neck cancer therapeutics, supportive care products and lung cancer and Head & Neck cancer diagnostics.
  • The content of this Master Class focuses on the most important information for pharmaceutical, biotech and laboratory executives, and, Health Care Professionals who treat lung cancer, mesothelioma, and/or Head and Neck cancer. The presentation topics range from the epidemiology, testing, diagnosis, staging and therapies and includes the overall patient management of Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (NSCLC), Mesothelioma, and advanced or metastatic Head & Neck Cancer.
  • This Master Class is taught by a distinguished faculty of academic KOLs who are the experts in NSCLC, SCLC, Mesothelioma and Head & Neck cancer.
  • This Master Class is a comprehensive review for industry executives with ANY level of experience. The October 11 & 12, 2018 dates were selected to follow the World Conference on Lung Cancer in Toronto and the 2018 ESMO meeting so as to provide the most current and new clinical and scientific information on the thoracic malignancies.
  • This Lung Cancer Master Class for Pharmaceutical Executives®” has been specifically designed as an advanced-level, "immersion" training program for industry executives who want or need a comprehensive clinical/scientific update on thoracic malignancies. In ADDITION, it affords an increasingly rare opportunity to meet, interact with, and establish relationships or strengthen your rapport with the expert KOL lung cancer and head and neck cancer academic faculty. Where else can you meet personally for two days with the top lung cancer and Head & Neck cancer KOLs, most of whom are the academic oncologists who have been the primary investigators on the key recent and ongoing clinical trials. Feedback from the previous Master Classes strongly indicates that this ability to meet personally with the faculty is extremely valuable and reason itself to attend this Master Class.
  • This Master Class uses a very highly-interactive effective and enjoyable learning format constantly engaging the faculty and audience. Each KOL’s presentation includes at least one interactive patient case-study with corresponding treatment-related questions for the audience to answer. Most presentations begin with a few “Rapid-Fire” questions to immediately engage the audience and assess baseline level of knowledge on key and unresolved clinical issues for improving patient outcome. Also, by using their “smart devices” connected to our private Master Class WI-Fi network, the audience is able to ask questions of the KOL faculty throughout the Master Class from the privacy of their seats in the audience. These audience-asked questions are “queued-up” for the KOL faculty to answer at the numerous expert panel discussions and Q&A sessions. The audience will “up-vote” many questions to help ensure that the most important questions are answered by the KOL faculty at the numerous Expert Panel Discussions and Q & A Sessions.
  • There are many other opportunities designed in this Master Class to help each member of the audience to establish personal relationships with the KOL faculty. There’s a private reception on Day 1, followed by a private dinner with several KOL academic lung cancer and Head and Neck cancer experts. There are two full breakfasts and lunches, plus morning and afternoon beverage and snack breaks each day. In addition, during some presentations, members of the audience might find it more beneficial to meet with some of the faculty.
2-day "immersion" training program on LUNG CANCER and HEAD & NECK CANCER for pharmaceutical, biotech and diagnostic/laboratory executives who want a comprehensive update. There is significant new information and many new drugs for these thoracic malignancies.
Quad
Seating is limited. For group discounts click here → steve.madison@bmli.com.
October 11 & 12, 2018Dallas, TX
TAUGHT BY A DISTINGUISHED ACADEMIC FACULTY OF
LUNG CANCER AND HEAD & NECK CANCER EXPERTS
Cancer Master Class
Dr. Bunn
Dr. Bunn
Co-Chair
  Dr. West
Dr. West
Co-Chair
Continuing Education
THE FOLLOWING ARE CONFIRMED FACULTY TO DATE — OTHERS PENDING
Dr. Curran
Dr. Curran
Dr. Drilon
Dr. Drilon
Dr. Natale
Dr. Natale
Dr. Weiss
Dr. Weiss
Dr. Borghaei
Dr. Borghaei
Dr. Riely
Dr. Riely
Dr. Gralla
Dr. Gralla
Dr. Garon
Dr. Garon
Dr. Davies
Dr. Davies
Dr. Schiller
Dr. Schiller
Dr. Merrick
Dr. Merrick
Dr. Ramalingam
Dr. Ramalingam
Dr. Tsao
Dr. Tsao
Dr. Koeller
Dr. Koeller

 
Day 1 - October 11, 2018
7:00AM
REGISTRATION/CHECK-IN
7:00AM
BUFFET BREAKFAST FOR ALL PARTICIPANTS AND KOL FACULTY
8:00AM
WELCOME, INTRODUCTIONS, OBJECTIVES & CME/CE PRE-TEST
Steve Madison Confirmed
SESSION 1
Non-Small Cell Lung Cancer: Etiology, Epidemiology, Staging, Testing (Chair: J. Schiller Confirmed)
8:30AM
EPIDEMIOLOGY, ETIOLOGY, AND STAGING OF LUNG CANCER
J. Schiller Confirmed
RAPID-FIRE Demographic Audience Questions
  1. Early-Stage (I - III) NSCLC patients should routinely receive testing for driver mutations. YES? NO? UNCERTAIN?
  2. Approximately 10% of lung cancer occurs in NEVER smokers. YES? NO? UNCERTAIN?
  3. Approximately 95% of smokers will never develop lung cancer. YES? NO? UNCERTAIN?
Content Highlights
  • Incidence and prevalence
  • Patient demographics
  • Diagnosing and staging
  • Brief pathology review (100% needed to make a cancer DX); Staging before testing and diagnostics
  • Causes & Risk factors: Hereditary, Genetics, Mutations
  • CT Chest Scans and other imaging scans
  • Non-Small Cell Lung Cancer (NSCLC) versus Small Cell Lung Cancer (SCLC)
  • NSCLC: Nonsquamous versus Squamous Histologies
  • SCLC: Extensive versus Limited Disease
8:50AM
Q & A
9:00AM
DEBATE #1: TUMOR MUTATIONAL BURDEN (TMB) IS A CLINICALLY USEFUL “TOOL” FOR MANAGING NSCLC PATIENTS TODAY
  • Yes - H. Jack West Confirmed
  • No - J. Schiller Confirmed
9:20AM
Expert Panel Discussion and Q&A
9:30AM
DEBATE #2: MOLECULAR MARKER TESTING FOR DRIVER MUTATIONS SHOULD BE USED ROUTINELY DONE IN EARLY-STAGE, POTENTIALLY CUREABLE, NSCLC PATIENTS (Stages I - IIIA)
  • Yes - R. Natale Confirmed
  • No - H. Borghaei Confirmed
9:50AM
Expert Panel Discussion and Q&A
10:00AM
BREAK
10:20AM
MOLECULAR TESTING AND TESTING STANDARDS OF CARE FOR LUNG CANCER PATIENTS
D. Merrick Confirmed
RAPID-FIRE Demographic Audience Questions
  1. All treatment-naïve, lung cancer patients should receive NGS testing: YES? NO? UNCERTAIN?
  2. All treatment-naïve, lung cancer patients should receive testing for PD-L1. YES? NO? UNCERTAIN?
  3. All treatment-naïve, lung cancer patients should receive ALL possible tests before initiating systemic therapy: NGS testing for rare lung cancer driver mutations, EGFR, ALK and ROS1 mutation testing, and, testing for PD-L1 levels. YES? NO? UNCERTAIN?
Content Highlights
  • Standards of care for molecular testing in treatment-naïve lung cancer patients
  • Standards of care for testing lung cancer patients after relapse
  • What is the role of PD-L1 testing? Other predictive biomarkers for checkpoint inhibition?
  • Broader NGS testing become a standard of care? How does NGS testing broaden or change what oncologists treating lung cancer should be doing as a standard of care?”
  • Which molecular or genetics tests should be conducted for which patients and when?
  • Testing for non-resistant EGFR mutations, uncommon EGFR mutations, EGFR insertions and deletions
10:40AM
Q&A
SESSION 2
Early-Stage NSCLC (Chair W. Curran Confirmed)
11:00AM
 EARLY-STAGE NSCLC (Stages I - III): MANAGEMENT OF PATIENTS WITH NOVEL RADIATION STRATEGIES
W. Curran Confirmed
RAPID-FIRE Questions
  1. I understand the standards of care for treating early-stage NSCLC with radiation therapy. YES? NO? UNCERTAIN?
  2. I am aware of the new and emerging radiation strategy therapies for treating early-stage NSCLC as potential cures. YES? NO? UNCERTAIN?
Content Highlights
  • Defining early-stage NSCLC patients: Staging, Prevalence, Incidence; Goals of Therapy: Why New cases versus death are a true unmet need (magnitude) show chart from Facts & Figures
  • Brief pathology review (100% needed to make a cancer DX); Staging before testing and diagnostics
  • Causes & Risk factors: Hereditary, Genetics, Mutations
  • CT Chest Scans and other imaging scans
  • Clinical Implications on prognosis and therapy decisions of detecting lung cancer early
  • Multidisciplinary (pathology, surgery, radiation (DX+TX), medical oncology, other HCPs)
  • Adjuvant versus Neo-adjuvant
  • Why is Stage IIIA vs. IIIB so important? (e.g., Cisplatin vs Carboplatin-based regimens)
  • Systemic options: chemotherapy, targeted therapy, immune therapy
  • Standards of Care vs. Investigational use in clinical trials (including targeted therapies & immune therapies)
  • SBRT and Non-surgical alternatives for early-stage, medically inoperable and increasingly operable NSCLC patients who do not want surgery.
11:20AM
Q & A
11:30AM
EARLY-STAGE NSCLC (Stages I – IIIA): NEW AND EMERGING STRATEGIES USING TARGETED THERAPY AS A POTENTIAL CURE
S. Ramalingam Confirmed
RAPID-FIRE Questions
  1. I know which early-stage-NSCLC patients who are potentially curable YES? NO? UNCERTAIN?
Content Highlights
  • Treating Stage IIIA NSCLC with consolidation, systemic immune therapy.
  • Is there ONE or are there more than one standards of care?
  • Will the clinical data on the various emerging strategies of immune therapies likely create additional standards of care?
11:50AM
Expert Panel Discussion and Q & A
12:00PM
LUNCH FOR ALL PARTICIPANTS AND KOL FACULTY
1:00PM
EARLY-STAGE NSCLC (Stages I – IIIA): NEW AND EMERGING STRATEGIES USING IMMUNE THERAPY AS A POTENTIAL CURE
H. Borghaei Confirmed
RAPID-FIRE Questions
  1. I understand the standard(s) of care for using immune therapy for treating early-stage NSCLC?
Content Highlights
  • FDA approved and emerging options
  • Key clinical trials
1:20PM
EXPERT PANEL DISCUSSION AND Q & A
SESSION 3
NSCLC-Advanced/Metastatic (Chair: E. Garon Confirmed)
1:30PM
DEBATE #3: PROGRESSION-FREE SURVIVAL (PFS) BENEFIT ALONE IS SUFFICIENT TO REPLACE OVERALL SURVIVAL (OS) AS A STANDARD OF CARE ENDPOINT FOR SELECTING FIRST-LINE THERAPY IN NSCLC?
  • Yes - H. West Confirmed
  • No - R. Natale Confirmed
1:45PM
Expert Panel Discussion and Q & A
2:00PM
THE STANDARDS OF CARE FOR INITIAL THERAPY OF NON-SQUAMOUS NSCLC
E. Garon Confirmed
RAPID-FIRE Questions
  1. I understand the standards of care for treatment-naïve NSCLC patients using immune therapy. YES? NO? UNCERTAIN?
  2. I understand the roles of using dual immune therapies for treatment-naïve NSCLC patients. YES? NO? UNCERTAIN?
  3. I understand the emerging options involving using immune therapies in combination with targeted therapies and chemotherapies for treatment-naïve NSCLC patients. YES? NO? UNCERTAIN?
Content Highlights
  • Understand the heterogeneity of NSCLC and the clinical impact of distinguishing among subpopulations, especially different histologies and different subtypes.
  • Which patients and for which options?
  • Algorithms and emerging therapies
  • Immune Therapies, Targeted Therapies, Chemotherapies
  • Monotherapies versus Combinations
  • Combinations of any of the above, especially dual immune checkpoint inhibition combinations, immune therapies in combinations with targeted therapies, immune therapies in combinations with chemotherapies
2:20PM
EXPERT PANEL DISCUSSION AND Q & A
2:40PM
BREAK
3:00PM
THE STANDARDS OF CARE FOR INITIAL SYSTEMIC THERAPY OF SQUAMOUS NSCLC
J. West Confirmed
RAPID-FIRE Questions
  1. I understand how to select systemic therapy in treatment-naïve NSCLC patients? YES? NO? UNCERTAIN?
Content Highlights
  • How are the standards of care options identified and selected for specific patients?
  • Targeted therapy: Targeting VEGFR2, non-resistant EGFR mutations
  • Immune therapies
  • Chemotherapies
  • Monotherapies versus Combinations
  • Combinations of any of the above, especially dual immune checkpoint inhibition combinations, immune therapies in combinations with targeted therapies, immune therapies in combinations with chemotherapies
3:20PM
EXPERT PANEL DISCUSSION AND Q & A
3:40PM
THE STANDARDS OF CARE FOR SALVAGE THERAPY FOR NSCLC PATIENTS WITH OR WITHOUT DRIVER MUTATIONS, AND FOR ALL HISTOLOGIES
R. Natale Confirmed
RAPID-FIRE Questions
  1. I understand the standards of care for treating relapsed NSCLC patients for NSCLC . YES? NO? UNCERTAIN?
Content Highlights
  • Which patients are candidates for which therapy?
  • How are all relapsed NSCLC patients sequenced fort salvage therapy?
4:00PM
EXPERT PANEL DISCUSSION AND Q & A
4:20PM
DEBATE #4: MOST NSCLC PATIENTS WITH LIMITED RESIDUAL DISEASE AFTER FIRST-LINE THERAPY SHOULD RECEIVE LOCAL CONSOLIDATION THERAPY OR MAINTENANCE THERAPY.
  • Yes - H. West Confirmed
  • No - E. Garon Confirmed
4:40PM
Expert Panel Discussion and Q & A
5:00PM
DAY ONE SESSIONS ADJOURN
6:00PM
RECEPTION for "MEETING KOL Faculty" and Networking with Industry Colleagues
This is one of many opportunities for pharmaceutical industry participants to meet one-on-one and establish and/or strengthen relationships with the KOLs on the expert faculty who is available & also for industry colleagues, advertising agencies and consultants to network with their colleagues in therapeutic, diagnostic and supportive care companies.
7:00PM
DINNER for "MEETING KOL Faculty" and Networking with Industry Colleagues
This is another of many opportunities for pharmaceutical industry participants to meet one-on-one and establish and/or strengthen relationships with the KOLs on the expert faculty who is available & also for industry colleagues, advertising agencies and consultants to network with their colleagues in therapeutic, diagnostic and supportive care companies.
To register now click here or call 214-269-2014.
Day 2 - October 12, 2018
7:00AM
BUFFET BREAKFAST FOR ALL PARTICIPANTS AND KOL FACULTY
SESSION 4
ALK-Rearrangement and EGFR-Mutated Non-Small Lung Cancer (Chair: P. Bunn Confirmed)
8:00AM
ALK-NSCLC: FIRST-LINE THERAPIES, AND, SEQUENCING THERAPY FOR RELAPSED PATIENTS
P. Bunn Confirmed
RAPID-FIRE Questions
  1. There is clearly one anti-ALK agent recognized TODAY as the standard of care for most ALK-rearrangement-positive NSCLC patients. YES? NO? UNCERTAIN?
Content Highlights
  • Therapy selections and sequencing in a very crowded market: 1st, 2nd & 3rd- generation ALK-directed therapies of numerous FDA approved and emerging ALK-directed therapies
  • When to switch from targeted therapy for NSCLC patients with the ALK-gene rearrangement to chemotherapy?
  • Rethinking the use of immune therapy: When is immunotherapy an appropriate option for ALK-positive NSCLC patient?
  • Implications of CNS disease involvement and control in ALK-directed decision making
  • Use the most effective ALK-directed TKI “up front”? Or save the most effective TKI for last?
8:20AM
Expert Panel Discussion and Q&A
8:40AM
EGFR-NSCLC: FIRST-LINE THERAPIES, AND, SEQUENCING THERAPY FOR RELAPSED PATIENTS
G. Riely Confirmed
RAPID-FIRE Questions
  1. • There is clearly one anti-EGFR agent recognized TODAY as the standard of care for most EGFR-positive NSCLC patients. YES? NO? UNCERTAIN?
Content Highlights
  • Therapy selections and sequencing in a very crowded market: 1st, 2nd & 3rd- generation EGFR-directed therapies of numerous FDA approved and emerging EGFR-directed therapies
  • Mechanisms of resistance following first-line therapy for EGFR-positive patients
  • When to switch from EGFR-directed targeted therapy to chemotherapy?
  • Rethinking the use of immune therapy: When is immunotherapy an appropriate option for EGFR-positive NSCLC patient?
  • Implications of CNS disease involvement and control in anti-EGFR decision making
  • Use the most effective EGFR-directed TKI “up front”? Or save the most effective EGFR-directed TKI for last?
9:00AM
Expert Panel Discussion and Q&A
9:20AM
DEBATE #5: IS NGS WORTH WAITING FOR? DELAY STARTING INITIAL SYSTEMIC THERAPY FOR TREATMENT-NAÏVE NSCLC PATIENTS WHO ARE EGFR-, ALK-, OR ROS1-POSITIVE, TO ACCOMMODATE NGS TESTING FOR THE “NEW” DRIVER MUTATIONS
  • Delay starting initial systemic therapy in treatment-naïve NSCLC patients who are EGFR-, ALK-, or ROS1-positive, until receiving NGS testing results - P. Bunn Confirmed
  • Do not delay starting initial systemic therapy while waiting for NGS testing results in NSCLC patients who are EGFR-, ALK-, or ROS1-positive - G. Riely Confirmed
9:40AM
Expert Panel Discussion and Q&A
10:00AM
BREAK
10:20AM
THE “NEW” & EMERGING DRIVER MUTATIONS IN LUNG CANCER
A. Drillon Confirmed
RAPID-FIRE Questions
  1. I understand why NGS testing has made the testing for mutations “beyond EGFR, ALK and ROS1” an important potential option treatment-naive NSCLC patients.
Content Highlights
  • BRAF V600E
  • MEK
  • MET
  • mTOR
  • HER-2
  • KRAS
  • non-resistant EGFR mutations
  • Other EGFR insertions, deletions
10:40AM
Expert Panel Discussion and Q&A
SESSION 5
Small Cell Lung Cancer & Mesothelioma & Elderly Lung Cancer Patients (Chair: A. Tsao Confirmed)
11:00AM
SMALL CELL LUNG CANCER (SCLC): What are the standards of care and the emerging systemic therapeutic options?
P. Bunn Confirmed
RAPID-FIRE Questions
  1. I understand the “approved” immune therapy for SCLC. YES? NO? UNCERTAIN?
  2. I am aware of the clinical data using emerging targeted therapy and immune therapy for SCLC. YES? NO? UNCERTAIN?
Content Highlights
  • Emerging data with targeted therapies
  • Emerging data with immune therapies
  • Limited Disease: initial therapy and after patient prognoses; overall patient management
  • Extensive Disease: initial therapy and after patient prognoses; overall patient management
  • Role of Radiation with systemic therapy: prophylactic cranial Irradiation & chest radiation
  • Standards of Care vs. Investigational therapies in clinical trials: Initial & salvage therapies
11:20AM
MESOTHELIOMA AND PLEURAL EFFUSIONS: What are the standards of care and the emerging systemic therapeutic options?
A. Tsao Confirmed
RAPID-FIRE Questions
  1. I understand the current standards of care for treating patients with mesothelioma. YES? NO? UNCERTAIN?
  2. I understand the emerging therapies for treating patients with mesothelioma. YES? NO? UNCERTAIN?
Content Highlights
  • Incidence, diagnosis, histology and current treatment algorithms for mesothelioma
  • Unmet medical needs in prolonging PFS and OS in patients with mesothelioma
  • Role of immune therapy in mesothelioma
  • Role of multi-modality therapy in mesothelioma
  • Role of angiogenesis and related growth factor signaling pathways in that pathology of pleural mesothelioma
  • Anti-angiogenic agents and emerging data with oral angiokinase inhibitors in pleural mesothelioma
11:40AM
Expert Panel Discussion and Q & A
NOON
LUNCH FOR ALL PARTICIPANTS AND KOL FACULTY
1:00PM
DEBATE #6 ELDERLY LUNG CANCER PATIENTS SHOULD NOT BE CONSIDERED ELIGIBLE FOR FULL DOSES OF SYSTEMIC THERAPY (AGE >65 YEARS)
  • NO: They should be considered to receive full doses of systemic therapy - J. Weiss Confirmed
  • YES: They should not be considered to receive full doses of systemic therapy - P. Bunn Confirmed
1:20PM
Expert Panel Discussion and Q&A
SESSION 6
Head & Neck Cancer (Chair: J. Weiss)
1:40PM
EPIDEMIOLOGY, ETIOLOGY, STAGING OF SQUAMOUS CELL CANCER OF THE HEAD & NECK (SCCHN)
J. Weiss Confirmed
RAPID-FIRE Questions
  1. Head and neck cancer is twice as prevalent in males vs. females. YES? NO ? UNCERTAIN?
Content Highlights
  • Incidence, diagnosis, histology
  • HPV-associated versus other causes of head and neck cancer
  • Which are the relevant biomarkers?
  • Should PD-L1 expression be measured? If so, when?
  • Recurrent/metastatic versus locally advanced disease
2:00PM
Expert Panel Discussion and Q & A
2:10PM
CANCER OF THE HEAD & NECK: SYSTEMIC THERAPY STANDARDS OF CARE AND EMERGING COMBINATION THERAPY OPTIONS – IMMUNE THERAPY, TARGETED THERAPY, CHEMOTHERAPY
J. Weiss
RAPID-FIRE Questions
  1. I understand the standards of care for recurrent/metastatic patients with Squamous Cell Carcinoma of the Head & Neck (SCCHN). YES? NO? UNCERTAIN?
  2. Immune therapies are approved only for second-line therapy of recurrent/metastatic patients with Squamous Cell Carcinoma of the Head & Neck (SCCHN). YES? NO? UNCERTAIN?
  3. Is PD-L1 expression a valid biomarker for predicting response to checkpoint inhibition and other immune therapy?
Content Highlights
  • Treatment of recurrent/metastatic patients with Squamous Cell Carcinoma of the Head & Neck (SCCHN) with: Immune therapies, targeted therapies chemotherapies, alone & in combination
  • Managing locally advanced patients with SCCHN with: Immune therapies, targeted therapies chemotherapies, alone & in combination
  • First-line therapies versus salvage regimens, especially following platinum-based initial therapy
  • Other head & neck cancers: Metastatic Cutaneous Squamous Cell, and Recurrent or Metastatic Nasopharyngeal Cancer.
2:30PM
Expert Panel Discussion and Q & A
2:45PM
BREAK
3:05PM
THE ROLE OF SUPPORTIVE CARE AND PALLIATIVE CARE FOR LUNG CANCER AND HEAD & NECK CANCER PATIENTS
R. Gralla Confirmed
RAPID-FIRE Questions
  1. I understand the differences between “palliative” & “supportive” care. YES? NO? UNCERTAIN?
  2. I understand what is the definition of “best supportive care. YES? NO? UNCERTAIN?
  3. Supportive care should be initiated at the start of systemic anti-cancer therapy. YES? NO? UNCERTAIN?
Content Highlights
  • Why is it so important to initiate supportive/palliative care at the same time as starting anticancer drug therapy?
  • Review of the common supportive care interventions for lung cancer: Control of nausea and vomiting, loss of appetite, fatigue, depression, anxiety, pain, etc., and the role of growth factors
  • What is the importance of quality of life as it relates to palliative and supportive care?
  • Standards of care vs. Investigational use in clinical trials
  • anti-emetics, growth factors, bone metastases, opioids and other pain strategies, opioid constipation, managing alopecia, anorexia/cachexia, the role of steroids
3:25PM
Expert Panel Discussion and Q & A
3:40PM
MANAGING TOXICITIES WITH SYSTEMIC THERAPY FOR LUNG CANCER AND HEAD & NECK CANCER
M. Davies Confirmed
RAPID-FIRE Questions
  1. After nearly a decade of experience with immune therapy checkpoint inhibitors, primarily in melanoma and lung cancer, most community-based oncologists are comfortable using immune therapies and managing their toxicities. TRUE? FALSE?
  2. In some practices (both private and academia) the patient is sometime “demanding” immune therapy for their lung cancer despite the evidence that a targeted therapy of a chemotherapy is clearly the optimal choice as documented by the published literature and guidelines. TRUE? FALSE?
Content Highlights
  • Immune-Related Adverse Events (irAEs) with Immune Therapies, including dual combinations of immune therapy and other immune therapy combinations
  • What are the most common types of toxicities associated with immune therapy for lung cancer?
  • One way to learn about these toxicities is analogous to auto immune disease.
  • The oncology nurse or Nurse Practitioner is critically important for successful use of immune therapy.
  • Shared decision making and patient-centered care are part of the new treatment and patient management paradigm using immune therapy for lung cancer.
  • What will the future bring with combinations of either dual checkpoint inhibition of checkpoint inhibition plus a targeted therapy
  • What are we learning from the treatment of melanoma with combination regimens using immune therapy?
  • Issues associated with new and emerging toxicities targeted therapies
  • The Physician/Nurse and Patient/Family partnership
4:00PM
Expert Panel Discussion and Q & A
4:15PM
CLINICAL PATHWAYS & VALUE-BASED CARE: OPTIMIZING THERAPIES TO IMPROVE OUTCOMES
J. Koeller Confirmed
RAPID-FIRE Questions
  1. I understand how value is defined for anti-cancer therapy. Yes? No?
  2. I understand MACRA. YES? NO?
  3. I understand what is meant by a clinical pathway for lung cancer care. Yes? No? ‘
  4. Most payers consider _____% compliance acceptable for clinical pathways. A) at least 50% B) approximately 60% C) approximately 70% D) approximately 80%
Content Highlights
  • Identify all of the components involving all aspects of diagnosis and therapy of NSCLC in to order to develop an optimal therapy
  • Identify the clinical and financial benefits of a NSCLC pathway as it relates to patient care, resource utilization -- including testing, drug selection, pathway compliance and outcomes.
  • Which clinical pathways are viable options to everyone? How does an oncologist best select the most appropriate options? Pros and cons? Why? What is the future?
  • How are specific NSCLC pathways developed, implemented, used and monitored? What is the future?
4:35PM
Expert Panel Discussion and Q & A
4:55PM
POST-TEST for CME/CE - P. Bunn Confirmed
5:00PM
MASTER CLASS ADJOURNS

Master Class Objective & Executive Summary top

The overall objective of this live, 2-day Master Class, and the archived Internet webinars as enduring materials for one year available approximately 3 months following the live program in Dallas, is to provide much needed training on lung cancer and Head & Neck Cancer to the executives within pharmaceutical and biotech companies and diagnostic/laboratory companies, especially those who are new or relatively new to these malignancies. In addition, this Cancer Master Class training initiative is also designed to help non-industry Health Care Professionals (HCPs) who provide patient care, to better understand the most recent clinical developments regarding thoracic cancer therapeutics, supportive care products and testing/diagnostics.

The FOCUS of this two-day Master Class will be on the most important and most common areas of what drugs, supportive care and diagnostic tests are used for lung cancer and Head & Neck Cancer. The Master Class agenda has been structured so that the expert KOL faculty helps pharmaceutical biotech and diagnostic/laboratory companies to provide better service to their customers: the oncologists, pathologists, fellows, nurses pharmacists and other HCPs involved in delivering care to their patients with lung cancer and Head & Neck Cancer.

What makes this Master Class so unique is that it is a CME/CE-accredited or certified course that utilizes academic and cancer leaders in ancillary areas as the course faculty. The Oncology Learning Center® has accredited this course for 16 hours of CME/CE credit because many, if not the majority of the executives within pharmaceutical, biotech and diagnostic/laboratory companies, are physicians, nurses, pharmacists and other HCPs. The Oncology Learning Center has also intentionally made this Master Class a CME/CE event so that no commercial interests could be a part of the faculty and to help avoid any type of commercial influence. This Master Class is therefore an objective, unbiased review of the current and emerging therapies, diagnostics, tests and supportive care for lung cancer and Head & Neck Cancer.

Outside of this Master Class, pharmaceutical and biotech industry and diagnostic/laboratory industry professionals of various health care disciplines have very limited opportunities to engage with the KOLs, who for the most part, are the experts who are typically any or all of the following: Principal Investigators of key clinical trials; authors of publications and abstracts from key trials; authors of many textbook chapters on lung cancer and Head & Neck Cancer; committee members of various guidelines and other professional organizations such as the International Association for the Study of Lung Cancer and the American Society of Clinical Oncology.

Therefore, we have designed this 2-day Master Class to focus on the needs that are based upon medical and scientific research that both the clinical and marketing pharmaceutical industry executives must thoroughly understand in order to be proficient in their various industry positions involving drugs, diagnostics and supportive care for thoracic malignancies.

The comprehensive agenda on this Website describes in great detail the content of this Cancer Master Class on Lung Cancer and Head & Neck Cancer. In addition, the expert academic and leading ancillary expert faculty members and their biographies are provided.

The educational format or learning design of this Master Class is one that is intentionally highly interactive. From the beginning through the final panel discussion, all presentations, session and panels are structured so that the audience can ask questions of the expert faculty. And vice-versa, the faculty will be asking questions of the audience throughout the entire program.

To receive CME/CE credit, the learners attending this Master Class have three weeks following the program to complete the required program survey (on line), and to successfully answer the knowledge test questions found on Oncology Learning Center Website for this Master Class. All of the PowerPoint® slides, recorded audio and PowerPoint slide presentations will be available for download and "24/7" immediately following the Master Class.

NOTE: PLEASE bring your own "Smart Devices" to interact with the Master Class faculty
Please bring your iPhones, iPads, Tablets, Androids, Laptop Computers, etc., to this Cancer Master Class. Smart Devices connected to our private Master Cass Network will enable you and the other Master Class participants to use your personal smart devices to ask any questions of the faculty throughout the program from your seats in the audience, and also, to enable you and others in the audience to answer the numerous questions of each faculty member during their presentations.

Unmet Medical and Educational Needs

In 2018, lung cancer will again be the leading cause of cancer deaths in the USA. It remains a significant unmet medical need, and, is expected to remain a major clinical and scientific challenge for the foreseeable future, despite recent advances in many different therapeutic classes including immune therapy and targeted therapy used as monotherapy and also in various combinations including with chemotherapy. According to the American Cancer Society Facts and Figures there were an estimated 225,000 new cases, and 160,000 deaths from lung cancer this in 2017. Survival rates for patients with lung cancer vary widely depending upon the stage of the lung malignancy when it is initially diagnosed. The five-year survival rate for Stage I NSCLC is approximately 50 percent. Perhaps more importantly, because most lung cancer are diagnosed at late stages of disease, especially Stages II and mostly IV, the five-year survival rate for Stage IV NSCLC is approximately two percent. Thus, it is clear that there is incredible opportunity for improving outcomes for patients with lung cancer. Despite the overall poor outcomes, lung cancer patient outcomes are improving. Patients are living longer and with a better quality of life because physicians and other healthcare professionals have access to the information to gain the knowledge and competence to treat, care for and manage their patients. Physicians have a better understanding of lung cancer cell biology, an increasing ability to personalize existing and emerging systemic lung cancer drug therapy because of molecular and genomic diagnostic tests, the availability to use next-generation systemic lung cancer therapy and expanded uses of many existing systemic lung cancer drug therapies.

In 2018 Head & Neck Cancer there will be approximately 50,000 new cases and 9,700 patients who will die from this malignancy. Like lung cancer it remains a significant unmet medical need, and, is expected to remain a major clinical and scientific challenge for the foreseeable future, despite recent advances in many different therapeutic classes including immune therapy and targeted therapy used as monotherapy and also in various combinations including with chemotherapy. A survey of Clinical Trials.gov reveals more than 1,000 clinical trials evaluating strategies for treating Head & Neck Cancer. Despite the overall poor outcomes, like with lung cancer, Head & Neck Cancer patient outcomes are improving. Patients are living longer and with a better quality of life because physicians and other healthcare professionals have access to the information to gain the knowledge and competence to treat, care for and manage their patients. Physicians have a better understanding of Head & Neck Cancer cell biology, an increasing ability to personalize existing and emerging systemic drug therapy because of molecular testing, the availability to use immune and targeted therapies like with lung cancer patients and the expanding uses of many existing systemic drug therapies for Head & Neck Cancer.

Target Audience top

The target audience for this CME/CE Master Class on Lung Cancer and Head & Neck Cancer is primarily the executives working in pharmaceutical and biotech companies and in the diagnostic/laboratory companies who are involved in the area of lung cancer and Head and Neck Cancer. These include executives who are either in Medical Affairs, Medical Scientific Liaisons (MSLs), Thought leader Liaisons, clinical development, R&D, or any area of commercialization such as sales, marketing and marketing research. Medical, surgical and radiation oncologists, pathologists, and other HealthCare Professionals (HCPs) such as nurses, Advanced Nurse Practitioners, Physician Assistants, and pharmacists in private practice, as well as oncology/hematology fellows are also invited to attend.

And finally, anyone else who may not be a HCP, but rather are important and integral members of the chain of professionals involved directly or indirectly in the delivery of care to cancer patients are also invited to “audit this Master Class for no CME/CE credit.” This is especially true for many marketing and sales executive but it also includes consultants, and other corollary personnel such as executives of advertising agencies. The inclusion of everyone from various backgrounds, especially in a limited group of 90 participants, will only help to facilitate an important interactive dialogue during this two-day Master Class.

Learning Objectives

Physicians

  1. Understand the epidemiology, etiology and staging of lung cancer and head and neck cancer.
  2. Compare and contrast the different molecular tests and predictive and prognostic biomarkers for NSCLC patients and head and neck cancer patients.
  3. Understand the benefits and risks of waiting for NGS test results for treatment-naïve NSCLC patients with an EGFR mutation or an ALK- or ROS1-rearrangement before initiating systemic therapy.
  4. Compare and contrast the various FDA approved drugs and also the emerging therapeutic options for both treatment-naïve and refractory/relapsed non-squamous NSCLC patients, including immune therapy, chemotherapy and targeted therapy used in combination strategies and as monotherapies.
  5. Compare and contrast the various FDA approved drugs and also the emerging therapeutic options for both treatment-naïve and refractory/relapsed squamous NSCLC patients, including immune therapy, targeted therapy and chemotherapy used in combination strategies and as monotherapies.
  6. Evaluate the various opportunities with systemic therapy and local therapy for treating early-stage lung cancer in patients with and without driver mutations.
  7. Analyze the various current standards of care and emerging strategies for treating Small Cell Lung Cancer patients.
  8. Compare and contrast the various 1st -, 2nd, - and 3rd-generation FDA approved and emerging drug options for treating NSCLC patients with EGFR-, ALK- and ROS1-directed therapies.
  9. Evaluate the current and emerging treatment options for mesothelioma.
  10. Understand the FDA approved and emerging therapeutic options for advanced or metastatic squamous cell carcinoma of the head and neck in the up front and relapsed settings.
  11. Evaluate the various options for palliative and supportive care for lung cancer patients and head and neck cancer patients.
  12. Understand the pros and cons of clinical pathways for treating thoracic malignancies.

Pharmacist

  1. Describe the epidemiology, etiology and staging of lung cancer and head and neck cancer.
  2. Identify the different molecular tests and predictive and prognostic biomarkers for NSCLC patients and head and neck cancer patients.
  3. Define the benefits and risks of waiting for NGS test results for treatment-naïve NSCLC patients with an EGFR mutation or an ALK- or ROS1-rearrangement before initiating systemic therapy.
  4. Recall the various FDA approved drugs and also the emerging therapeutic options for both treatment-naïve and refractory/relapsed non-squamous NSCLC patients, including immune therapy, chemotherapy and targeted therapy used in combination strategies and as monotherapies.
  5. Recall the various FDA approved drugs and also the emerging therapeutic options for both treatment-naïve and refractory/relapsed squamous NSCLC patients, including immune therapy, targeted therapy and chemotherapy used in combination strategies and as monotherapies.
  6. List the various opportunities with systemic therapy and local therapy for treating early-stage lung cancer in patients with and without driver mutations.
  7. Recall the various current standards of care and emerging strategies for treating Small Cell Lung Cancer patients.
  8. Describe the various 1st -, 2nd, - and 3rd-generation FDA approved and emerging drug options for treating NSCLC patients with EGFR-, ALK- and ROS1-directed therapies.
  9. Define the current and emerging treatment options for mesothelioma.
  10. List the FDA approved and emerging therapeutic options for advanced or metastatic squamous cell carcinoma of the head and neck in the up front and relapsed settings.
  11. Identify the various options for palliative and supportive care for lung cancer patients and head and neck cancer patients.
  12. Describe the pros and cons of clinical pathways for treating thoracic malignancies.

Nurses and Advanced Nurse Practitioners

  1. Describe the epidemiology, etiology and staging of lung cancer and head and neck cancer.
  2. Identify the different molecular tests and predictive and prognostic biomarkers for NSCLC patients and head and neck cancer patients.
  3. Define the benefits and risks of waiting for NGS test results for treatment-naïve NSCLC patients with an EGFR mutation or an ALK- or ROS1-rearrangement before initiating systemic therapy.
  4. Recall the various FDA approved drugs and also the emerging therapeutic options for both treatment-naïve and refractory/relapsed non-squamous NSCLC patients, including immune therapy, chemotherapy and targeted therapy used in combination strategies and as monotherapies.
  5. Recall the various FDA approved drugs and also the emerging therapeutic options for both treatment-naïve and refractory/relapsed squamous NSCLC patients, including immune therapy, targeted therapy and chemotherapy used in combination strategies and as monotherapies.
  6. List the various opportunities with systemic therapy and local therapy for treating early-stage lung cancer in patients with and without driver mutations.
  7. Recall the various current standards of care and emerging strategies for treating Small Cell Lung Cancer patients.
  8. Describe the various 1st -, 2nd, - and 3rd-generation FDA approved and emerging drug options for treating NSCLC patients with EGFR-, ALK- and ROS1-directed therapies.
  9. Define the current and emerging treatment options for mesothelioma.
  10. List the FDA approved and emerging therapeutic options for advanced or metastatic squamous cell carcinoma of the head and neck in the up front and relapsed settings.
  11. Identify the various options for palliative and supportive care for lung cancer patients and head and neck cancer patients.
  12. Describe the pros and cons of clinical pathways for treating thoracic malignancies.

CME & CE Credit top

This symposium provides 16 hours of CME credit to physicians, 16 hours of CNE credit to nurses, 16 hours of CPE credit to pharmacists, and a Certificate of Attendance for fellows and other HCPs for receiving 16 hours of credit from their professional organizations and accrediting societies.

Accreditation Statements top

Physicians

The BioMedical Learning Institute (BMLI) is proud to have earned the prestigious 6-year “Accreditation with Commendation” status as an elite provider of continuing medical education (CME) for physicians. The BioMedical Learning Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. BMLI is accredited through March 2023.

The BioMedical Learning Institute designates this live activity for a maximum of 16 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists

The BioMedical Learning Institute (BMLI) is proud to have earned the maximum 6-year accreditation status from the Accreditation Council for Pharmacy Education as a provider of continuing education (CPE) for pharmacists. BMLI is accredited through June 2023.

The BioMedical Learning Institute is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0838-0000-18-002-L01-P
Credits: 16 hours (1.6 ceus)
Type of Activity: Knowledge

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Nurses

The BioMedical Learning Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The BioMedical Learning Institute designates this educational activity for 16 contact hours.

Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

To receive CE contact hour credit, attendance at the entire activity and the successful completion of the post‐test and evaluation form is required.

Other

Physician Assistants: AAPA accepts certificates of attendance for educational activities certified for Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician Assistants may receive a maximum of 16 hours of Category 1 credit for attending this symposium.

Fellows will receive a certificate of attendance that they can submit to their accrediting organizations for continuing education credit.

Hotel (Location) top

This Cancer Master Class will be conducted at the Grand Hyatt Hotel DFW International Airport located in Terminal D which is very conveniently located inside the Dallas/Ft. Worth (DFW) International Airport.

We have secured 90 sleeping rooms at a discounted room rate of $259 per night (single and double occupancy) at the Grand Hyatt DFW. Triple occupancy is $284. Quadruple occupancy is $309. All of these discounted rates are exclusive of applicable taxes which are estimated at 13%. The cut-off date or last date that you can reserve a discounted sleeping room is September 26, 2018.

Click here to reserve the $259 discounted sleeping room.

The contact information is:
2337 S International Pkwy, Dallas, TX 75261
Phone: (972) 973-1234

Please note #1: There are two Hyatt hotels located inside the Dallas (DFW) Ft. Worth International Airport. One is the Grand Hyatt DFW (inside Terminal D) where the Lung Cancer Master Class will be held and where we have reserved sleeping rooms at a special discounted rate. Detailed hotel information is provided above.

Please note #2: As is the situation in many cities in the United States, there is another major airport servicing the Dallas and Ft. Worth, Texas cities and surrounding areas: That airport is Dallas Love Field which is the national (US) hub and headquarters of Southwest Airlines.

The Dallas Love Field airport is located approximately 30 miles away from Dallas Fort Worth (DFW) International airport, where the Master Class will be conducted. Depending upon ground automobile traffic this will be between a 30-and 90-minute taxi drive between these two airports (Dallas Love Field and DFW International) plus approximately an $80 taxi fare. Also, please note that Southwest Airlines DOES NOT service Dallas Ft. Worth (DFW) International Airport.

Therefore, it is highly advisable that all executives flying to Dallas to attend the Master Class use an airline that flies to Dallas Ft. Worth (DFW) International airport (the location of the Lung Cancer Master Class) and NOT to Dallas Love Field which is mandatory if you fly Southwest Airlines. Southwest does not fly to Dallas Fort Worth International Airport (DFW).

  • Executives who need or want an in-depth, comprehensive and up=to-date review on lung cancer, Head & Neck cancer or both, involving either therapeutics, supportive care products and diagnostics.
    • Medical Affairs, Clinical development, R & D
    • MSLs (Medical Scientific Liaisons)
    • KOL/Thought Leader Liaisons
    • Marketing, Marketing Research
    • Sales Management/Sales
    • Commercial Development, Business Development
    • Training Directors, Managers and Associates
    • Strategic planning and development Managers, Directors or VPs
  • Advertising Agency Executives and Writers, Market Research Companies
  • Medical Communication Executives and oncology writers and editors
  • Consultants
  • Publication Planners
  • Clinical Research Organizations (CROs), Investment Bankers
  • A limited number of private-practice oncologists, nurses, pharmacists, and other HCPs typically attend. 95% of the audience will be from industry. 5% will be practicing clinicians.
  • This Lung Cancer and Head & Neck Cancer Master Class is the ONLY practical and cost-effective way for anyone to become current regarding the information that a pharmaceutical industry executive needs to know in a two-day period.
  • Attending this Lung Cancer and Head & Neck Cancer Master Class provides a major benefit: establishing personal relationships with the lung cancer and head & neck cancer KOLs while learning in an immersion course.
  • No other such lung cancer and head & neck cancer immersion training course exists.
  • Today, there is so much new information on so many current, new and emerging lung cancer and head & neck cancer therapeutics, supportive care products and diagnostics, as well as new indications for existing lung cancer and head & neck cancer drugs.
  • Within the R&D pipelines of numerous pharmaceutical companies, there is an ever increasing number of lung cancer therapeutics, supportive care products and diagnostics, many of which will become FDA approved.
  • Can you afford not to attend this Master Class on lung cancer and head & neck cancer and not to be the most competitive within your industry regarding lung cancer and head & neck cancer?
  • Because this Master Class is taught by the top-tier expert KOLs in lung cancer and head & neck cancer, it affords a rare opportunity to personally meet and get to know the KOLs.
  • During the two days of the program, there is a one-hour welcome reception on day one, plus several meal functions where individual KOL faculty members are assigned separate tables to enable pharmaceutical industry participants to sit with the KOLs of their choice: one formal dinner, two buffet breakfasts, and two buffet lunches. There are also four beverage breaks. With a limit of participants there is ample time for personal meetings with the KOLs.
  • In most oncology pharmaceutical companies, only the sales representatives receive formal lung cancer training of any kind. In addition, your customers, the practicing oncologists, hematologists and other cancer HCPs are required to take 30 hours of oncology/hematology CME or CE training annually. Therefore, how do cancer executives like yourself receive this essential training? How do you keep current? How do retain your competitive advantage, especially with the KOLs?
  • Private practice medical oncologists/hematologists and related cancer HCPs will benefit from this three-day update by the academic experts and by networking with the pharmaceutical/diagnostic industry executives.
© 2018 Oncology Learning Center, Inc.